NewAmsterdam Pharma Company N.V. $NAMS Stock Holdings Increased by Adage Capital Partners GP L.L.C.

Key Points

• Adage Capital Partners increased its stake in NewAmsterdam Pharma by 85.8% in Q1, owning 1,950,650 shares valued at approximately $39.93 million, as per the latest SEC filing.
• A total of nine analysts have given NewAmsterdam Pharma a "Buy" rating, with an average price target of $41.55 as the company aims to enhance therapies for metabolic diseases.
• Insider trading activity includes a significant sale by CEO Johannes Jacob Piete Kastelein, who sold 50,000 shares for around $1.21 million, indicating a 29.53% reduction in his ownership of the stock.

Adage Capital Partners GP L.L.C. increased its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 85.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,950,650 shares of the company's stock after acquiring an additional 900,650 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 1.78% of NewAmsterdam Pharma worth $39,930,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. RA Capital Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 14.6% in the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock worth $207,544,000 after acquiring an additional 1,293,938 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 1.3% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 16,116,418 shares of the company's stock worth $329,903,000 after acquiring an additional 200,000 shares during the period. Maverick Capital Ltd. increased its holdings in shares of NewAmsterdam Pharma by 57.0% in the 1st quarter. Maverick Capital Ltd. now owns 549,469 shares of the company's stock worth $11,248,000 after acquiring an additional 199,464 shares during the period. Caption Management LLC increased its holdings in shares of NewAmsterdam Pharma by 341.3% in the 1st quarter. Caption Management LLC now owns 30,934 shares of the company's stock worth $633,000 after acquiring an additional 43,756 shares during the period. Finally, Quarry LP acquired a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth about $25,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded up $1.34 during trading hours on Friday, hitting $27.00. 1,570,503 shares of the company's stock traded hands, compared to its average volume of 806,032. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $27.29. The company's fifty day simple moving average is $22.98 and its two-hundred day simple moving average is $20.56. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -16.67 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. On average, analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

NAMS has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Stifel Nicolaus began coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Citigroup began coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Wells Fargo & Company began coverage on shares of NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price for the company. Finally, Royal Bank Of Canada increased their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and an average target price of $41.55.

Insider Activity

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares of the company's stock, valued at approximately $2,897,845.58. This represents a 29.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Louise Frederika Kooij sold 18,073 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $25.09, for a total transaction of $453,451.57. Following the sale, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at $376,350. This represents a 54.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 12,835 shares of company stock valued at $248,134 and sold 274,954 shares valued at $5,899,406. 20.84% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.